190 related articles for article (PubMed ID: 3875310)
1. Amoxicillin-clavulanic acid in the treatment of lower respiratory tract infections caused by beta-lactamase-positive Haemophilus influenzae and Branhamella catarrhalis.
Wallace RJ; Steele LC; Brooks DL; Luman JI; Wilson RW; McLarty JW
Antimicrob Agents Chemother; 1985 Jun; 27(6):912-5. PubMed ID: 3875310
[TBL] [Abstract][Full Text] [Related]
2. Amoxicillin/clavulanate therapy of respiratory tract infections: a microbiologic perspective.
Cunha BA
Clin Ther; 1992; 14(3):418-25. PubMed ID: 1638583
[TBL] [Abstract][Full Text] [Related]
3. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.
Cooper CE; Slocombe B; White AR
J Antimicrob Chemother; 1990 Sep; 26(3):371-80. PubMed ID: 2121699
[TBL] [Abstract][Full Text] [Related]
4. Bacteriologic failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae.
Patel JA; Reisner B; Vizirinia N; Owen M; Chonmaitree T; Howie V
J Pediatr; 1995 May; 126(5 Pt 1):799-806. PubMed ID: 7752010
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of amoxicillin plus clavulanic acid against Haemophilus influenzae and Branhamella catarrhalis.
Liljequist BO; Gezelius L
Eur J Clin Microbiol; 1986 Dec; 5(6):615-21. PubMed ID: 3492374
[TBL] [Abstract][Full Text] [Related]
6. Amoxycillin/clavulanate in acute purulent exacerbations of chronic bronchitis.
Maesen FP; Davies BI; Baur C
J Antimicrob Chemother; 1987 Mar; 19(3):373-83. PubMed ID: 3494724
[TBL] [Abstract][Full Text] [Related]
7. Amoxicillin-potassium clavulanate: a novel beta-lactamase inhibitor.
Smith BR; LeFrock JL
Drug Intell Clin Pharm; 1985 Jun; 19(6):415-20. PubMed ID: 3891282
[TBL] [Abstract][Full Text] [Related]
8. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate.
Thorburn CE; Molesworth SJ; Sutherland R; Rittenhouse S
Antimicrob Agents Chemother; 1996 Dec; 40(12):2796-801. PubMed ID: 9124843
[TBL] [Abstract][Full Text] [Related]
9. Amoxycillin-clavulanic acid combination in bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis. Preliminary report.
Thornley PE; Aitken JM; Nichol GM; Slevin NJ
Drugs; 1986; 31 Suppl 3():113-4. PubMed ID: 3525087
[TBL] [Abstract][Full Text] [Related]
10. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Pottumarthy S; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
[TBL] [Abstract][Full Text] [Related]
12. Comparison of amoxycillin/clavulanate with amoxycillin in children and adults with chronic obstructive pulmonary disease and infection with Haemophilus influenzae.
Jensen T; Pedersen SS; Stafanger G; Høiby N; Koch C; Bondesson G
Scand J Infect Dis; 1988; 20(5):517-24. PubMed ID: 3065925
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.
Doern GV; Tubert TA
Diagn Microbiol Infect Dis; 1990; 13(4):349-52. PubMed ID: 2127558
[TBL] [Abstract][Full Text] [Related]
14. The effect of augmentin on sputum beta-lactamase activity in patients with cystic fibrosis.
Penketh AR; Hodson ME; Batten JC
Br J Clin Pract; 1984 May; 38(5):188-9. PubMed ID: 6610437
[No Abstract] [Full Text] [Related]
15. A randomized controlled trial of amoxicillin plus clavulanate compared with cefaclor for treatment of acute otitis media.
Marchant CD; Shurin PA; Johnson CE; Murdell-Panek D; Feinstein JC; Fulton D; Flexon P; Carlin SA; Van Hare GF
J Pediatr; 1986 Nov; 109(5):891-6. PubMed ID: 3534203
[TBL] [Abstract][Full Text] [Related]
16. Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects.
Weber DJ; Tolkoff-Rubin NE; Rubin RH
Pharmacotherapy; 1984; 4(3):122-36. PubMed ID: 6739312
[TBL] [Abstract][Full Text] [Related]
17. A combination of amoxicillin and clavulanic acid in the treatment of respiratory tract infections caused by amoxicillin-resistant haemophilus influenzae.
Beeuwkes H; Rutgers VH
Infection; 1981; 9(5):244-8. PubMed ID: 7028635
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of amoxycillin/clavulanic acid and five other oral antibiotics against clinical isolates of Haemophilus influenzae and Branhamella catarrhalis.
Fernández-Roblas R; Jiménez Arriero M; Rodriguez-Tudela JL; Soriano F
J Antimicrob Chemother; 1988 Dec; 22(6):867-72. PubMed ID: 3149634
[TBL] [Abstract][Full Text] [Related]
19. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.
Pichichero ME; Doern GV; Kuti JL; Nicolau DP
Paediatr Drugs; 2008; 10(6):391-7. PubMed ID: 18998749
[TBL] [Abstract][Full Text] [Related]
20. [Serotype distribution and drug resistance of
Tian HL; Shi W; Zhou HF; Yuan L; Yao KH; Rexiati D; Xu AM
Zhonghua Er Ke Za Zhi; 2018 Apr; 56(4):279-283. PubMed ID: 29614568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
